C-JCOGSignum Biosciences
lipid ligand mimetics, STMs, botanical extracts
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JCOG
C-JCOGC-JCOGlipid ligand mimetics, STMs, botanical extracts
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Signum Biosciences lipid ligand mimetics, STMs, botanical extracts
Signum Biosciences, Inc. describes itself as a biopharmaceutical company focused on discovery and development of innovative products for consumer and medical needs. Its work centers on compounds and botanical extracts that mimic natural lipid ligands involved in cellular regulation and signaling. The company also develops skincare technologies, including Epicutis, using patented ingredients and simplified formulations.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Signum Biosciences — Early mechanism · Bottom quartile. Derived deterministically from 10 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic